GALLIUM GA 68 EDOTREOTIDE Drug Patent Profile

Which patents cover Gallium Ga 68 Edotreotide, and what generic alternatives are available?

Gallium Ga 68 Edotreotide is a drug marketed by Methodist and Uihc Pet Imaging and is included in two NDAs.

The generic ingredient in GALLIUM GA 68 EDOTREOTIDE is gallium ga-68 edotreotide. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium ga-68 edotreotide profile page.

Summary for GALLIUM GA 68 EDOTREOTIDE

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for GALLIUM GA 68 EDOTREOTIDE

GALLIUM GA 68 EDOTREOTIDE is protected by zero US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Methodist	GALLIUM GA 68 EDOTREOTIDE	gallium ga-68 edotreotide	SOLUTION;INTRAVENOUS	218845-001	Oct 10, 2025	AP	RX	No	No
Uihc Pet Imaging	GALLIUM GA 68 EDOTREOTIDE	gallium ga-68 edotreotide	SOLUTION;INTRAVENOUS	210828-001	Aug 21, 2019	AP	RX	Yes	Yes

Gallium Ga 68 Edotreotide Investment Scenario and Fundamentals Analysis: Market Status, Exclusivity Timeline, Patent Estate Strength, and Generic/Biosimilar Entry Risk

Last updated: July 14, 2026

Gallium Ga 68 edotreotide (Ga 68 edotreotide) is a radiopharmaceutical used for neuroendocrine tumor (NET) imaging. The investment profile is driven by (1) constrained supply-chain economics and utilization rates, (2) IP and regulatory barriers tied to radiochemistry process know-how and labeling, and (3) competitive substitution risk versus other Ga-68 and F-18 NET imaging agents. In practice, equity-like upside is tied to uptake and reimbursement durability, while downside is tied to manufacturing bottlenecks, compendial/label shifts, and defensibility of process and formulation IP rather than classic small-molecule “composition of matter” breadth.

What is Ga 68 edotreotide and where does it fit in NET imaging?

Ga 68 edotreotide is a somatostatin receptor (SSTR)-targeted imaging agent, administered intravenously for PET imaging of somatostatin receptor-positive NETs (including well-differentiated NETs). Investment relevance comes from modality and clinical positioning: it is an imaging product, not a therapeutic radiopharmaceutical, so revenue is correlated to imaging volumes, departmental purchasing cycles, and nuclear medicine workflow economics rather than oncology drug durability alone.

What is the mechanism and dosing workflow investors underwrite?

• Target: SSTR (commonly assessed in NET care pathways)
• Administration: radiotracer injection
• Endpoint: imaging-based detection and staging support
• Operational constraint: radiochemistry production needs short-lived radionuclide logistics and strict release testing

How does Ga 68 edotreotide compete in PET NET imaging?

The competitive set generally includes:

• Ga-68 DOTATATE and Ga-68 DOTATOC (SSTR imaging agents)
• F-18 labeled alternatives (where available) that can offer longer half-life logistics for certain centers

Investment implication: substitutability often hinges on logistics, dosing standardization, reimbursement rates, and equipment compatibility more than “clinical superiority.” IP that covers manufacturing steps and tracer quality can still create durable advantage even if pharmacology is same-class.

What is the FDA regulatory status and Orange Book status of Ga 68 edotreotide?

Featured-snippet answer: Ga 68 edotreotide’s exclusivity and generic entry route in the US are governed by the approved radiopharmaceutical regulatory approval and listing status. For most radiopharmaceuticals, the critical question for investors is whether the product is listed in the FDA’s Orange Book and whether there is an exclusivity-relevant New Drug Application (NDA) that creates enforceable barriers to generic radiopharmaceutical substitutes.

How to treat Orange Book risk for radiopharmaceuticals?

For imaging radiopharmaceuticals, “generic” entry is often constrained by:

• radionuclide sourcing and manufacturing process equivalence
• release specifications and in-process controls
• stability and sterility assurance under radiochemistry constraints
• labeling and indication-specific requirements

Investment implication: even if composition-of-matter exclusivity expires, process and manufacturing control may remain a practical barrier. The legal question then becomes what is protected (formulation, process, chelator synthesis, intermediate compounds, quality specs) versus what the regulator requires for approval.

What investor metrics map to regulatory outcomes?

• NDA type and labeling (indication scope)
• Whether a 505(b)(2) pathway is used by challengers
• Exclusivity status at FDA (patent-listed and non-patent exclusivity components)
• Any FDA inspections or manufacturing consistency issues that could cause supply interruptions

What patents protect Gallium Ga 68 edotreotide, and how strong is the patent estate?

Featured-snippet answer: The strength of Ga 68 edotreotide’s patent estate should be evaluated on whether it includes (1) radiotracer composition/chelator-related claims, (2) production-process claims specific to Ga-68 complexation and purification, and (3) quality-control or formulation claims that are needed for release and are hard to “design around.”

Patent estate categories that matter for radiopharmaceutical investment

1. Chelator and conjugate claims
   • Claims covering the chelator-edotreotide construct, salt forms, and intermediates
2. Radiolabeling process claims
   • Ga-68 labeling conditions, purification steps, kit configuration, and reaction timing
3. Formulation and kit claims
   • Excipients, buffer systems, lyophilization or solution forms, and kit stability
4. Method-of-use claims
   • Imaging protocols, dosage regimens, and patient selection language linked to specific SSTR imaging purposes

How many patents cover Ga 68 edotreotide?

A rigorous “how many” requires the Orange Book patent list and the associated patent-family inventory by jurisdiction. Under the current prompt, no patent numbers, listed patents, assignees, or jurisdiction-specific details are provided. Without those data, a quantified coverage count would be fabricated, which is not used.

How strong is patent defensibility in practice?

For radiopharmaceuticals, defensibility commonly depends less on broad composition claims alone and more on:

• production process specificity (temperature, pH windows, reaction duration)
• purification constraints that drive final impurity profile
• kit-specific conditions that affect radiochemical yield and specific activity

Investment implication: companies with process know-how and validated manufacturing can retain advantage even when “generic” legal claims look close to expiring.

When does Ga 68 edotreotide lose exclusivity, and what are the key expiration dates?

Featured-snippet answer: The relevant exclusivity and expiration timeline is determined by (1) patent expiry of any Orange Book-listed patents tied to the NDA and (2) any non-patent exclusivity (data exclusivity, marketing exclusivity) that applies to the NDA approval. The prompt provides no patent expiration dates or NDA-identifying details, so no accurate exclusivity calendar can be produced.

What timelines investors should anchor to

• Earliest composition-of-matter expiry
• Earliest process/formulation expiry
• Method-of-use expiry
• Any non-patent exclusivity expiry tied to the NDA approval date
• Expected generic filing windows for Paragraph IV or 505(b)(2) challenges (if any)

Investment implication: for radiopharmaceuticals, “generic-ready” typically requires both regulatory submission and operational manufacturing capability, so launch timing often lags the earliest legal date.

What generic entry risks exist for Ga 68 edotreotide?

Featured-snippet answer: The generic threat exists even when legal exclusivity is still active in a narrow time window because challengers can target alternative approval pathways. For radiopharmaceutical imaging agents, generic entry risk is often higher when (1) process claims are weak or easily designed around and (2) manufacturing capacity and radionuclide supply chains can scale reliably.

Paragraph IV litigation risk versus design-around

For classic small molecules, Paragraph IV is often the driver. For radiopharmaceuticals, the practical risk model is:

• Is there Orange Book listing that enables patent dispute leverage?
• Do challengers have a credible manufacturing parity plan?
• Are there multiple patents with staggered expiry that extend “effective” protection?

Investment implication: investors should model “effective exclusivity” based on operational and regulatory time-to-market, not just the legal date.

Substitution risk from other imaging agents

Even if Ga 68 edotreotide remains legally protected, market share can erode if:

• competing agents have better logistics (half-life advantages)
• reimbursement favors specific products
• supply reliability issues affect ordering behavior

What patent litigation affects Ga 68 edotreotide, and what settlements matter?

Featured-snippet answer: A litigation-driven entry path requires publicly identifiable suits, parties, asserted patents, and filing dates. The prompt provides no litigation docket data, parties, or patent assertions. Without those inputs, listing litigation outcomes or settlement terms would be unreliable and is not included.

What to look for in any Ga 68 edotreotide patent disputes (framework)

• District court and asserted patents
• Claimed design-around or invalidity theories
• Settlement provisions (entry date, market allocation, exclusivity carve-outs)
• Injunction scope and appeal posture
• Whether an NDA is carved into separate label or patient cohorts

Investment implication: litigation outcomes for radiopharmaceuticals can shape supply contracts and distribution agreements more directly than they shape prescription-only market share.

How does Ga 68 edotreotide compare with Ga-68 DOTATATE and Ga-68 DOTATOC on market and IP?

Featured-snippet answer: Competitive pressure from other SSTR PET imaging agents is typically product-agnostic pharmacology plus workflow economics. Investors should benchmark Ga 68 edotreotide against DOTATATE/DOTATOC on logistics, labeling, and manufacturing reliability, then overlay any differences in patent estate strength.

Comparison factors investors underwrite

• PET imaging agent choice patterns in nuclear medicine
• Shipment and delivery constraints given radionuclide half-life
• Radiochemical yield and impurity profile as proxies for operational reliability
• Label coverage: any differences in NET subtypes or patient eligibility can shift adoption

IP overlay for competitive set

• DOTATATE/DOTATOC IP estates may include chelator and labeling process improvements
• Differences in formulation and kit production know-how can matter as much as “composition” claims

What formulations and manufacturing methods are protected for Ga 68 edotreotide?

Featured-snippet answer: The strongest protection in radiopharmaceuticals often targets the manufacturing process and kit-level formulation that enables consistent radiolabeling yield and impurity control. In the absence of specific listed patents in the prompt, no patent-number-level mapping to “formulation” versus “manufacturing method” can be stated accurately.

Manufacturing barriers investors should treat as IP-adjacent

• radiolabeling reaction setup in controlled environments
• purification steps that drive final spec compliance
• release testing methods and acceptance criteria
• stability profiles affecting kit storage and cold-chain logistics
• contamination control and sterility assurance

Investment implication: Even when legal claims look narrow, manufacturing control and release testing can slow entry and preserve margins.

What licensing deals or commercial arrangements can drive returns for Ga 68 edotreotide?

Featured-snippet answer: Investment return is often shaped by distribution, hospital contracting, and supply agreements tied to reliability. The prompt provides no licensing deal terms, parties, or revenue-sharing structures, so no deal-specific analysis is produced.

Where value transfer typically occurs in radiopharmaceuticals

• CDMO-style or contract manufacturing arrangements that reduce fixed overhead
• Distribution agreements with nuclear medicine suppliers
• Hospital system tenders that lock in preferred agent status
• Internal patient flow economics tied to imaging scheduling capacity

Investment implication: companies with predictable supply chain economics can sustain unit volumes even if competitors exist.

What revenue and demand fundamentals drive Ga 68 edotreotide performance?

Featured-snippet answer: Demand is a function of NET diagnosis incidence, physician adoption of SSTR PET imaging, and the ability to deliver reliable radiotracer supply. Imaging products are sensitive to:

• diagnostic guidelines that influence scan utilization
• payer policy and reimbursement rates
• departmental throughput and patient scheduling constraints

Commercial variables investors should model

• Market penetration and switching behavior among SSTR PET agents
• Hospital conversion cycles in nuclear medicine
• Stockout or delayed deliveries and the resulting loss of future orders
• Price and payer mix stability

Key Takeaways

• Ga 68 edotreotide’s investment fundamentals are driven by imaging utilization, reimbursement durability, and supply-chain reliability more than by classic oncology pill-like dynamics.
• The patent estate should be assessed for process and kit-level radiolabeling protection, because radiopharmaceutical “generic” entry is often operationally gated even after legal dates.
• Generic and substitute risk comes in two layers: legal challenges (Orange Book/patent listing) and practical substitution by competing SSTR PET agents with different logistics and labeling.
• A defensible exclusivity timeline and litigation-driven launch calendar cannot be quantified from the information provided in the prompt; any investment underwriting should anchor to the NDA’s Orange Book patent list and active dockets.

FAQs

1. How do investors estimate effective exclusivity for radiopharmaceutical imaging agents like Ga 68 edotreotide when legal expiry is near?
   By modeling manufacturing readiness time, release spec compliance, radionuclide logistics, and hospital tender cycles, not only the earliest patent expiry.

2. What is the primary risk to market share for Ga 68 edotreotide: generic entry or substitution by other SSTR PET tracers?
   Substitution risk is often the near-term driver because workflow and logistics can shift ordering even without immediate legal entry.

3. What types of patents most commonly sustain protection for Ga 68 radiopharmaceutical kits?
   Radiolabeling process, kit formulation, and impurity/release-related manufacturing control claims.

4. What reimbursement factors can most quickly change Ga 68 edotreotide demand?
   Payer policy shifts, imaging coverage rules for NET staging, and product-specific reimbursement differentials across hospital systems.

5. How should investors evaluate manufacturing/IP barriers against “generic” radiotracer launches?
   Use a combined assessment of process-specific claim scope, validated radiochemical yield consistency, and regulatory approval requirements for equivalence and release testing.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-14)
2. FDA. Guidance for Industry: ANDAs, 505(b)(2), and patent listing/exclusivity frameworks. U.S. Food and Drug Administration. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs (accessed 2026-07-14)